IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
GR Jones, M Lyons, N Plevris, PW Jenkinson, C Bisset… - Gut, 2019 - gut.bmj.com
Objective IBD prevalence is estimated to be rising, but no detailed, recent UK data are
available. The last reported prevalence estimate in the UK was 0.40% in 2003. We aimed to …
available. The last reported prevalence estimate in the UK was 0.40% in 2003. We aimed to …
The ACE (albumin, CRP and endoscopy) index in acute colitis: a simple clinical index on admission that predicts outcome in patients with acute ulcerative colitis
RK Grant, GR Jones, N Plevris… - Inflammatory bowel …, 2021 - academic.oup.com
Background Intravenous (IV) steroids remain the first-line treatment for patients with acute
ulcerative colitis (UC). However, 30% of patients do not respond to steroids, requiring …
ulcerative colitis (UC). However, 30% of patients do not respond to steroids, requiring …
Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease
N Plevris, PW Jenkinson, ID Arnott… - European journal of …, 2020 - journals.lww.com
Objective Limited data are available regarding the relationship between anti-tumor necrosis
factor (TNF) drug/antibody levels and perianal fistula outcomes in Crohn's disease. The aims …
factor (TNF) drug/antibody levels and perianal fistula outcomes in Crohn's disease. The aims …
Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn's disease
N Plevris, J Fulforth, M Lyons, SI Siakavellas… - Clinical …, 2021 - Elsevier
Background & Aims The level of fecal calprotectin (FC) correlates with endoscopic evidence
of inflammation in Crohn's disease (CD). A treat-to-target algorithm for patients with CD, that …
of inflammation in Crohn's disease (CD). A treat-to-target algorithm for patients with CD, that …
Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-naïve …
LAAP Derikx, HW Dolby, N Plevris… - Journal of Crohn's …, 2021 - academic.oup.com
Abstract Background and Aims Multiple adalimumab [ADA] biosimilars are now approved for
use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain …
use in inflammatory bowel disease [IBD]; however, effectiveness and safety data remain …
Implementation of CT-P13 via a managed switch programme in Crohn's disease: 12-month real-world outcomes
N Plevris, GR Jones, PW Jenkinson, M Lyons… - Digestive Diseases and …, 2019 - Springer
Abstract Background Switching from Remicade to CT-P13 allows for significant cost savings
and has been shown to be non-inferior to continued therapy with Remicade for the treatment …
and has been shown to be non-inferior to continued therapy with Remicade for the treatment …
Higher adalimumab drug levels during maintenance therapy for Crohn's disease are associated with biologic remission
N Plevris, M Lyons, PW Jenkinson… - Inflammatory Bowel …, 2019 - academic.oup.com
Background Adalimumab is an established treatment for Crohn's disease. Limited data are
available regarding the relationship between adalimumab drug levels and serum/fecal …
available regarding the relationship between adalimumab drug levels and serum/fecal …
Real‐world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort
N Plevris, J Fulforth, S Siakavellas… - Journal of …, 2021 - Wiley Online Library
Abstract Background and Aim Ustekinumab is a monoclonal antibody that targets interleukin‐
12/23. In Scotland, it was approved for the treatment of moderate to severe Crohn's disease …
12/23. In Scotland, it was approved for the treatment of moderate to severe Crohn's disease …
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis
M Lyons, LAAP Derikx, J Fulforth… - Alimentary …, 2022 - Wiley Online Library
Objective It is unclear how the compounding prevalence of inflammatory bowel disease
(IBD) has translated into the causes and rates of hospitalisation, particularly in an era of …
(IBD) has translated into the causes and rates of hospitalisation, particularly in an era of …
Analysis of colectomy rates for ulcerative colitis in pre‐and postbiological eras in Lothian, Scotland
PW Jenkinson, N Plevris, M Lyons, R Grant… - Colorectal …, 2021 - Wiley Online Library
Aim Biological treatment is effective in maintaining remission in ulcerative colitis (UC),
although the effect on colectomy rates remains unclear. In the UK the use of antitumour …
although the effect on colectomy rates remains unclear. In the UK the use of antitumour …